Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Dimopoulos, Meletios A, Goldschmidt, Hartmut, Niesvizky, Ruben, Joshua, Douglas, Chng, Wee-Joo, Oriol, Albert, Orlowski, Robert Z, Ludwig, Heinz, Facon, Thierry, Hajek, Roman, Weisel, Katja, Hungria,Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(17)30578-8
Date:
August, 2017
File:
PDF, 421 KB
english, 2017